Dr. David Gregg Wilding, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 600 W Hospital Rd, Brigham City, UT 84302 Phone: 435-734-2041 Fax: 435-723-8028 |
Dr. John Robert Markeson, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 1050 South Medical Drive, Ste 101, Brigham City, UT 84302 Phone: 435-538-1733 Fax: 435-538-1752 |
News Archive
Do T-cells play a protective immune role, or are they responsible for severe COVID-19 illness?
AVEO Oncology (NASDAQ: AVEO) and Astellas Pharma Inc. (TSE: 4503) announced overall survival (OS) for tivozanib, an investigational agent, from the Phase 3 TIVO-1 (TIvozanib Versus sOrafenib in 1st line advanced RCC) study in patients with advanced renal cell carcinoma (RCC). The final OS analysis, as specified by the protocol, shows a median OS of 28.8 months (95% confidence interval [CI]: 22.5–NA) for tivozanib versus a median OS of 29.3 months (95% CI: 29.3–NA) for the comparator arm, sorafenib.
The U.S. Food and Drug Administration today approved Defitelio (defibrotide sodium) to treat adults and children who develop hepatic veno-occlusive disease (VOD) with additional kidney or lung abnormalities after they receive a stem cell transplant from blood or bone marrow called hematopoietic stem cell transplantation (HSCT).
Genmab's revenues were DKK 107 million (USD 19 million) for the first quarter of 2010. In the same period of 2009, Genmab recognized revenues of DKK 250 million (USD 45 million).
› Verified 3 days ago